Gene Panel Market Report 2026

The gene panel market size has grown rapidly in recent years. It will grow from $2.47 billion in 2025 to $2.85 billion in 2026 at a compound annual growth rate (CAGR) of 15.3%. The growth in the historic period can be attributed to advancement in next-generation sequencing, reduced sequencing costs, clinical genetics adoption, expansion of diagnostic laboratories, oncology biomarker research.

The gene panel market size is expected to see rapid growth in the next few years. It will grow to $4.96 billion in 2030 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to growth in personalized medicine, expansion of hereditary disease testing, demand for precision diagnostics, integration of ai in genomic analysis, wider clinical adoption. Major trends in the forecast period include growing adoption of multi-gene diagnostic panels, increased use in cancer risk assessment, expansion of customized gene panel testing, rising demand for pharmacogenomic insights, integration of gene panels in clinical decision-making.

The rising prevalence of cancer is expected to drive the growth of the gene panel market in the coming years. Cancer is a group of diseases marked by the uncontrolled growth and spread of abnormal cells, which can invade and damage surrounding tissues and organs. The increasing incidence of cancer is attributed to factors such as aging populations, lifestyle changes, environmental exposures, and advancements in detection and diagnostic technologies. Gene panels support cancer management by enabling comprehensive genetic testing to identify mutations and alterations in specific genes, guiding personalized treatment strategies and improving patient outcomes. For example, in January 2023, PubMed, a US-based free search engine for biomedical and life sciences literature maintained by the United States National Library of Medicine, reported that 1,958,310 new cancer cases and 609,820 cancer-related deaths were projected to occur in the United States in 2023. Therefore, the growing prevalence of cancer is propelling the gene panel market.

Leading companies in the gene panel market are developing innovative technologies, such as oncology panels, to improve the accuracy, efficiency, and comprehensiveness of cancer diagnostics and personalized treatments. Oncology panels are specialized gene panels that analyze multiple cancer-associated genes to detect mutations and alterations, supporting diagnosis, prognosis, and therapy selection. For instance, in May 2023, Vizgen Inc., a US-based biotechnology company, launched the MERFISH PanCancer Pathways Panel, offering customizable options for researchers entering spatial genomics. These predesigned panels are optimized for error robustness, delivering reliable and reproducible results for various research applications, including cancer studies. By integrating spatial information with gene expression data, the panels provide deeper insights into tumor microenvironments and cellular interactions, enabling more targeted and personalized cancer research and therapeutic development. This launch represents a significant advancement in spatial biology, allowing researchers to explore complex biological systems with previously unattainable detail.

In May 2025, GeneDx Holdings Corp., a US-based provider of clinical genetic and genomic diagnostic testing, acquired Fabric Genomics for an undisclosed amount. Through this acquisition, GeneDx aims to strengthen its gene-panel testing capabilities and integrate AI-powered genomic interpretation to enhance diagnostic accuracy and expand its global services. Fabric Genomics, a US-based company, provides AI-driven genomic interpretation software that analyzes genetic sequencing data and assists clinical laboratories in identifying disease-causing variants.

Major companies operating in the gene panel market are F. Hoffmann-La Roche, Thermo Fisher Scientific, Quest Diagnostics, Eurofins Scientific, Agilent Technologies, Illumina, Qiagen, Myriad Genetics, Guardant Health, Invitae, Integrated DNA Technologies, Bio-Rad, Novogene, Fulgent Genetics, MedGenome, Centogene, Blueprint Genetics, BIONEER, BGI Group.

North America was the largest region in the gene panel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene panel market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gene panel market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gene panel market by increasing costs of imported sequencing reagents, testing kits, and laboratory equipment. Diagnostic centers and hospitals are most affected due to reliance on imported genomic technologies. These tariffs raise testing costs by increasing per-sample sequencing and analysis expenses, potentially limiting test adoption in routine diagnostics. However, they promote domestic development of genetic testing solutions, encouraging local production of panels, reagents, and supporting bioinformatics infrastructure.

The gene panel market research report is one of a series of new reports that provides gene panel market statistics, including gene panel industry global market size, regional shares, competitors with a gene panel market share, detailed gene panel market segments, market trends and opportunities, and any further data you may need to thrive in the gene panel industry. This gene panel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gene panels are collections of specific genes selected for testing in a single assay to evaluate genetic variations associated with particular diseases or conditions. They are used for diagnosing genetic disorders, identifying inherited diseases, and supporting personalized treatment plans by analyzing multiple genes simultaneously, often in the context of cancer, rare diseases, or other genetic conditions.

The main types of gene panel products and services include test kits and testing services. Test kits are pre-packaged tools containing all the necessary reagents and instructions for performing genetic analysis. They utilize various technologies, such as amplicon-based and hybridization-based methods, and can be either predesigned or customized. Gene panels are applied for cancer risk assessment, diagnosis of congenital diseases, pharmacogenetics, and other purposes, and are used by various end-users, including research institutes, hospitals, diagnostic centers, pharmaceutical companies, and others.

The gene panel market consists of revenues earned by entities by providing services such as custom panel design, next-generation sequencing, bioinformatics analysis, clinical interpretation, and pharmacogenomics services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gene panel market also includes sales of metabolic disorder panels, reproductive health panels, carrier screening panels, and neurological disorder panels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.